Survey
Two Week Delay: Survey on Wilson’s Disease & ALXN-1840 (February 2025)
Ticker(s): MNPR, AZNThe survey results include 13 physicians that manage 10 or more patients with Wilson’s Disease
How many patients with Wilson's disease do you treat?
Are you knowledgeable about the data for ALXN-1840?
How often do you meet with your Wilson's disease patients?
- Quarterly
- Bi-annually
- Annually
- Something else, please specify
What percentage (%) of your Wilson's disease patients are currently receiving standard of care copper chelation therapy?
How frequently do your Wilson's disease patients change between existing therapies? Please be specific.
What percentage (%) of your Wilson's disease patients currently receiving standard of care copper chelation therapy would be interested in an alternative agent?
What is the primary reason a Wilson's disease patient would want an alternative agent to standard copper chelation therapy? Select one.
- Safety/tolerability issues
- Limited efficacy on systemic copper removal
- Absence of cognitive benefit
- Out of pocket cost
- Something else, please specify
To what percentage (%) of Wilson's disease patients currently receiving standard of care copper chelation therapy would you offer ALXN-1840, if it were available today?
What is the primary reason a patient would want ALXN-1840 over standard of care copper chelation therapy? Select one.
- Improved safety/tolerability
- Improved efficacy on systemic copper removal
- Improved efficacy on cognitive function
- Potentially better pricing, out of pocket cost
- Something else, please specify
What is the primary reason a patient would not want ALXN-1840 over standard of care copper chelation therapy? Select one.
- Safety/tolerability concerns
- Comfort with the level of systemic copper removal with existing chelators
- Insufficient evidence on cognitive benefit
- Questions around out of pocket costs
- Something else, please specify
To what percentage (%) of Wilson's disease patients not currently receiving standard of care copper chelation therapy would you offer ALXN-1840, if it were available today?
To what percentage (%) of Wilson's disease patients would you offer ALXN-1840 in the first 12 months, if it were available today?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
